Your browser doesn't support javascript.
loading
Potential value of a rapid syndromic multiplex PCR for the diagnosis of native and prosthetic joint infections: a real-world evidence study.
Pascual, Stéphanie; Noble, Brooklyn; Ahmad-Saeed, Nusreen; Aldridge, Catherine; Ambretti, Simone; Amit, Sharon; Annett, Rachel; O'Shea, Shaan Ashk; Barbui, Anna Maria; Barlow, Gavin; Barrett, Lucinda; Berth, Mario; Bondi, Alessandro; Boran, Nicola; Boyd, Sara E; Chaves, Catarina; Clauss, Martin; Davies, Peter; Dianzo-Delgado, Ileana T; Esteban, Jaime; Fuchs, Stefan; Friis-Hansen, Lennart; Goldenberger, Daniel; Golle, Andrej; Groonroos, Juha O; Hoffmann, Ines; Hoffmann, Tomer; Hughes, Harriet; Ivanova, Marina; Jezek, Peter; Jones, Gwennan; Ceren Karahan, Zeynep; Lass-Flörl, Cornelia; Laurent, Frédéric; Leach, Laura; Horsbøll Pedersen, Matilde Lee; Loiez, Caroline; Lynch, Maureen; Maloney, Robert J; Marsh, Martin; Milburn, Olivia; Mitchell, Shanine; Moore, Luke S P; Moffat, Lynn; Murdjeva, Marianna; Murphy, Michael E; Nayar, Deepa; Nigrisoli, Giacomo; O'Sullivan, Fionnuala; Öz, Büsra.
Afiliação
  • Pascual S; bioMérieux, Marcy l'Etoile, France.
  • Noble B; bioMérieux, Salt Lake City, USA.
  • Ahmad-Saeed N; University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom.
  • Aldridge C; Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle Upon Tyne, United Kingdom.
  • Ambretti S; S. Orsola Bologna, Microbiology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
  • Amit S; Sheba Medical Center, Ramat Gan, Israel.
  • Annett R; University Hospital of Wales, Cardiff, Wales, United Kingdom.
  • O'Shea SA; University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom.
  • Barbui AM; San Giovanni Battista, Department of Public Health and Pediatrics Microbiology and Virology Unit, Città della Salute e della Scienza, Turin, Italy.
  • Barlow G; Hull University Teaching Hospitals NHS Trust, Hull, United Kingdom.
  • Barrett L; Oxford University Hospitals (OUH), Oxford, United Kingdom.
  • Berth M; AZ Alma, Eeklo, Belgium.
  • Bondi A; Department of Public Health and Pediatrics, University of Turin, Turin, Italy.
  • Boran N; Mater Misericordiae University Hospital, Dublin, Ireland.
  • Boyd SE; Chelsea and Westminster NHS Foundation Trust, London, United Kingdom.
  • Chaves C; Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal.
  • Clauss M; University Hospital Basel, Basel, Switzerland.
  • Davies P; NHS Greater Glasgow and Clyde, Glasgow Royal Infirmary, University of Glasgow, Glasgow, United Kingdom.
  • Dianzo-Delgado IT; Servicio de Microbiología, Hospital Universitario Ramón y Cajal and Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain.
  • Esteban J; Dept. of Clinical Microbiology, IIS-Fundación Jiménez Díaz, CIBERINFEC-CIBER de Enfermedades Infecciosas, Madrid, Spain.
  • Fuchs S; Institute of Hygiene and Medical Microbiology Medizinische Universität Innsbruck, Innsbruck, Austria.
  • Friis-Hansen L; Copenhagen University Hospital, Bispebjerg, Copenhagen, Denmark.
  • Goldenberger D; Dept. Clinical Microbiology at Rigshospitalet, Copenhagen, Denmark.
  • Golle A; University Hospital Basel, Basel, Switzerland.
  • Groonroos JO; NZOLH Maribor, Maribor, Slovenia.
  • Hoffmann I; Varsinais-Suomen sairaanhoitopiiri, Loimaa, Finland.
  • Hoffmann T; MVZ Labor Dr. Reising-Ackermann und Kollegen, Limbach Leipzig, Germany.
  • Hughes H; Sheba Medical Center, Ramat Gan, Israel.
  • Ivanova M; University Hospital of Wales, Cardiff, Wales, United Kingdom.
  • Jezek P; East Tallinn Central Hospital, Tallin, Estonia.
  • Jones G; Regional Hospital Príbram, Príbram, Czech Republic.
  • Ceren Karahan Z; University Hospital of Wales, Cardiff, Wales, United Kingdom.
  • Lass-Flörl C; Ankara University School of Medicine Department of Medical Microbiology, Ankara, Türkiye.
  • Laurent F; Institute of Hygiene and Medical Microbiology Medizinische Universität Innsbruck, Innsbruck, Austria.
  • Leach L; Hospices Civils de Lyon, Lyon, France.
  • Horsbøll Pedersen ML; Oxford University Hospitals (OUH), Oxford, United Kingdom.
  • Loiez C; Copenhagen University Hospital, Bispebjerg, Copenhagen, Denmark.
  • Lynch M; Dept. Clinical Microbiology at Rigshospitalet, Copenhagen, Denmark.
  • Maloney RJ; Centre Hospitalier Universitaire de Lille, Lille, France.
  • Marsh M; Mater Misericordiae University Hospital, Dublin, Ireland.
  • Milburn O; Hull University Teaching Hospitals NHS Trust, Hull, United Kingdom.
  • Mitchell S; Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle Upon Tyne, United Kingdom.
  • Moore LSP; Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle Upon Tyne, United Kingdom.
  • Moffat L; University Hospital of Wales, Cardiff, Wales, United Kingdom.
  • Murdjeva M; Chelsea and Westminster NHS Foundation Trust, London, United Kingdom.
  • Murphy ME; NHS Greater Glasgow and Clyde, Glasgow Royal Infirmary, University of Glasgow, Glasgow, United Kingdom.
  • Nayar D; University Hospital "St George", Plovdiv, Bulgaria.
  • Nigrisoli G; NHS Greater Glasgow and Clyde, Glasgow Royal Infirmary, University of Glasgow, Glasgow, United Kingdom.
  • O'Sullivan F; Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle Upon Tyne, United Kingdom.
  • Öz B; S. Orsola Bologna, Microbiology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
J Bone Jt Infect ; 9(1): 87-97, 2024.
Article em En | MEDLINE | ID: mdl-38601005
ABSTRACT

Introduction:

The BIOFIRE Joint Infection (JI) Panel is a diagnostic tool that uses multiplex-PCR testing to detect microorganisms in synovial fluid specimens from patients suspected of having septic arthritis (SA) on native joints or prosthetic joint infections (PJIs).

Methods:

A study was conducted across 34 clinical sites in 19 European and Middle Eastern countries from March 2021 to June 2022 to assess the effectiveness of the BIOFIRE JI Panel.

Results:

A total of 1527 samples were collected from patients suspected of SA or PJI, with an overall agreement of 88.4 % and 85 % respectively between the JI Panel and synovial fluid cultures (SFCs). The JI Panel detected more positive samples and microorganisms than SFC, with a notable difference on Staphylococcus aureus, Streptococcus species, Enterococcus faecalis, Kingella kingae, Neisseria gonorrhoeae, and anaerobic bacteria. The study found that the BIOFIRE JI Panel has a high utility in the real-world clinical setting for suspected SA and PJI, providing diagnostic results in approximately 1 h. The user experience was positive, implying a potential benefit of rapidity of results' turnover in optimising patient management strategies.

Conclusion:

The study suggests that the BIOFIRE JI Panel could potentially optimise patient management and antimicrobial therapy, thus highlighting its importance in the clinical setting.

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article